In a groundbreaking move set to transform diabetes management, Abbott and Medtronic have announced a global partnership aimed at integrating Abbott’s world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic’s insulin delivery systems.<\/p>\n
A Powerful Collaboration<\/strong><\/p>\n The partnership, revealed on August 7, 2024, brings together two giants in the healthcare industry. Abbott, known for its innovative CGM systems, will develop a sensor based on its FreeStyle Libre technology designed to work exclusively with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems.<\/p>\n Jared Watkin, executive vice president of Abbott’s diabetes care business, emphasized the significance of this collaboration: “This partnership pairs two global leaders in glucose sensing technology and insulin delivery. Connecting this CGM built for Medtronic’s insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.”<\/p>\n Expanding Access to Advanced Diabetes Management<\/strong><\/p>\n The integration aims to benefit over 11 million people globally who require multiple daily injections of rapid-acting insulin. By combining Abbott’s CGM sensor with Medtronic’s AID algorithms, the system will enable automatic adjustments of insulin to maintain glucose levels within a target range.<\/p>\n Que Dallara, executive vice president and president of Medtronic Diabetes, highlighted the partnership’s potential to expand access to advanced diabetes management tools: “We’re committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care.”<\/p>\n A Track Record of Success<\/strong><\/p>\n Abbott’s Libre portfolio has already demonstrated significant benefits for users:<\/p>\n – Improved glucose control With more than 6 million users across 60 countries, the FreeStyle Libre technology has set a new standard in diabetes care accessibility and ease of use.<\/p>\n Looking Ahead<\/strong><\/p>\n While financial terms and a timeline for commercial availability were not disclosed, this partnership marks a significant step forward in diabetes management. By combining Abbott’s sensing technology with Medtronic’s insulin delivery expertise, the companies aim to offer people with diabetes more choices and greater control over their condition.<\/p>\n As diabetes continues to affect millions worldwide, collaborations like this between industry leaders promise to drive innovation and improve outcomes for patients, bringing us closer to a future where managing diabetes is simpler and more effective than ever before.<\/p>\n
\n– Lower HbA1c levels
\n– Decreased diabetes-related hospital admissions
\n– Improved quality of life<\/p>\n